Results 111 to 120 of about 2,896 (157)
Bruton's Tyrosine Kinase Inhibitors: Mechanisms, Efficacy, Toxicities and Applications for the Treatment of Human Diseases. [PDF]
Sun M, Li D, Wei J.
europepmc +1 more source
Where next for BTKi-BCL2i combinations in mantle cell lymphoma? [PDF]
Eyre TA.
europepmc +1 more source
Comment on "EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation". [PDF]
Tedeschi A +12 more
europepmc +1 more source
Chylothorax as an Initial Presentation of Waldenström Macroglobulinemia: Report of Two Cases. [PDF]
Hamadah Y +5 more
europepmc +1 more source
An indirect comparison of zanubrutinib vs acalabrutinib plus venetoclax in patients with treatment-naive CLL. [PDF]
Shadman M +10 more
europepmc +1 more source
Cardiovascular Toxicity of BTK Inhibitors: A Patient-Centered Framework for Risk Stratification and Management. [PDF]
Tedeschi A +17 more
europepmc +1 more source
Bruton Tyrosine Kinase Inhibitor-Associated Pericardial Events by Agent and Generation.
Serra VSB +16 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:

